AKT1 and schizophrenia: By these criteria, the AKT inhibitor decreased kinase activity on four control substrates and two non-overlapping schizophrenia substrates, while increasing activity on six and zero substrates in the schizophrenia and control sample, respectively (Fig. 3a).